Author

Arlene H. Sharpe

Broad InstituteORCID 0000-0002-9736-2109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Assay:scRNA-seq· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Approach:benchmark study· 1

Frequent Co-Authors

Amy Y. HuangiD· 2 shared Emily J. RobitschekiD· 2 shared Jared H. RoweiD· 2 shared Alex Bastian· 1 shared Arnav MehtaiD· 1 shared Aziz M. Al’KhafajiiD· 1 shared Brian C. MilleriD· 1 shared Cassia Wang· 1 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amy Y. HuangORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ImmunologyeLifePeer-reviewedJul 8, 2026

Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis

Peter Georgiev, Sheila E. Johnson, Kiran Kurmi…·Arlene H. Sharpe

DOI 10.7554/elife.107745.3

mousebulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintJun 17, 2026

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors

Marc A. Schwartz, Dillon Lue, Mohammed Mutaher…·Nir Hacohen

The paper identifies Trim28 as a regulator of CD8 T cell differentiation in tumors using clonally-resolved CRISPR screens and shows its role in maintaining TCF7+ stem-like cells while impairing effector differentiation.

DOI 10.64898/2026.06.14.732162

𝕏 PostBluesky

ImmunologybioRxivPreprintFeb 8, 2026

Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy

Matthew P. Zimmerman, Amy Y. Huang, Emily K. Cox…·Brian C. Miller

This study shows CD40 agonist therapy reduces tumor growth in antigen presentation-deficient tumors by reprogramming monocytes and requiring IFN-gamma and CD8+ T cells for efficacy.

DOI 10.64898/2026.02.05.704029

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 29, 2024

Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas

Amy Y. Huang, Kelly P. Burke, Ryan M. Porter…·David Liu

The paper identifies HIF-2α as a therapeutic target for immune-infiltrated melanomas through stratified analysis of clinical and molecular data.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky